Recombinant Mouse B7 Homolog 4 is produced by our Mammalian expression system and the target gene encoding Phe29-Pro258 is expressed with a Fc tag at the C-terminus.
Greater than 95% as determined by reducing SDS-PAGE.
Anwendungsbeschreibung:
Redissolve: Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100µg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.. Endotoxin: Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test. Biological activity: Immobilized Anti-Human B7-H4 mAb(CatNC054) at 2µg/ml (100 µl/well) can bind Mouse B7-H4-Fc*(CatCS04).*: Biotinylated by NHS-biotin prior to testing The ED50 of Mouse B7-H4-Fc*(CatCS04) is 4.11 ng/ml. Background: Mouse V-set domain-containing T-cell activation inhibitor 1/VTCN1/B7-H4 is glycosylated member of the B7 family of immune co-stimulatory proteins. B7-H4 consists of extracellular domain (ECD) with one Ig-like V-set domain and one Ig-like C2-set domain. It is widely expressed, including in kidney, liver, lung, pancreas, placenta, prostate, spleen, testis and thymus. B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. It also involved in promoting epithelial cell transformation
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
